Dec 8th, 2017 - New Modalities for Genomic Profiling of HER2+ Breast Cancer From SABCS 2017 Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Dec 9th, 2017 - Dr Ivana Sestak speaks with ecancer at SABCS 2017 about screening for clinical variables to predict late distance disease recurrence among women with ER positive breast cancer following endocrine therapy.
Dec 9th, 2017 - Harpreet Singh speaks at a SABCS 2017 press session about how older women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6).
Dec 9th, 2017 - Dr Joseph Sparano speaks at a SABCS 2017 press session about how his findings show that a single positive CTC assay result five years after diagnosis provides independent prognostic information for late recurrence.
Dec 11th, 2017 - New Data on the Second Line Treatment of HER2+ Breast Cancer From SABCS 2017 Interview with Jame Abraham MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Dec 9th, 2017 - Prof Rowan Chlebowski speaks at a SABCS 2017 press session about how postmenopausal women who lose weight may have reduced breast cancer risk.
Dec 7th, 2017 - Rowan T. Chlebowski, MD, PhD, of the City of Hope National Medical Center, discusses 11-year followup results that showed a significantly lower breast cancer incidence among women with a greater than 5% weight loss (Abstract GS5-07).
Dec 8th, 2017 - Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients with trastuzumab-resistant disease (Abstract GS2-06).
Dec 7th, 2017 - Dr Fehrenbacher speaks at a SABCS 2017 press session about data from the randomised, phase III NSABP-B-47 clinical trial.
Dec 7th, 2017 - Dr Fehrenbacher speaks with ecancer at SABCS 2017 about a phase III trial of adjuvant chemotherapy with or without trastuzumab for HER2low invasive breast cancer.
Dec 6th, 2017 - Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).
Dec 8th, 2017 - Dr Gini Fleming speaks with ecancer at SABCS 2017 about the outcomes of the SOFT trial comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone.
Dec 14th, 2017 - William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, reviews the management of locoregional recurrence in breast cancer.
Dec 9th, 2017 - Dr Luigi Formisano speaks with ecancer at SABCS 2017 about breast cancer therapy resistance mediated by FGFR amplification.
Dec 12th, 2017 - N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, highlights four abstracts investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.
Dec 9th, 2017 - Dr Viviana Galimberti speaks with ecancer at SABCS 2017 about the role of axillary node dissection in modern breast cancer surgery.
Dec 12th, 2017 - Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic in Rochester, Minnesota, discusses four abstracts on preserving fertility in premenopausal breast cancer patients treated with chemotherapy
Dec 9th, 2017 - Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.
Dec 12th, 2017 - Maxine S. Jochelson, MD, of Memorial Sloan Kettering Cancer Center in New York, discusses four posters on the use of mammography, magnetic resonance imaging (MRI), and radiomics as biomarkers for treatment response
Dec 9th, 2017 - Prof Michael Gnant speaks with ecancer at SABCS 2017 to discuss the outcomes of a multi-centre phase III randomised trial of 2 or 5 years of anastrozole for post-menopausal breast cancer patients after 5 years of endocrine therapy.